Posted inClinical Updates Infectious Diseases news Public Health

Long-term Immunological and Clinical Outcomes of Monkeypox Virus Infection versus MVA-BN Vaccination: A 24-Month Longitudinal Cohort Analysis

This 24-month Belgian cohort study demonstrates that natural MPXV infection induces more durable and robust immunity than MVA-BN vaccination. While clinical symptoms mostly resolve within a year, persistent scarring remains common, and vaccine-induced immunity wanes significantly, highlighting the potential need for booster strategies.
Ensitrelvir Demonstrates Potent Antiviral Efficacy Comparable to Nirmatrelvir in Early COVID-19: Insights from the PLATCOV Trial
Posted inInfectious Diseases Internal Medicine news

Ensitrelvir Demonstrates Potent Antiviral Efficacy Comparable to Nirmatrelvir in Early COVID-19: Insights from the PLATCOV Trial

The PLATCOV trial identifies ensitrelvir as a highly effective oral antiviral, achieving rapid SARS-CoV-2 clearance comparable to ritonavir-boosted nirmatrelvir. This phase 2 adaptive trial suggests ensitrelvir is a viable alternative for outpatient management, potentially overcoming limitations associated with ritonavir-boosted regimens.
Strategic Release of Wolbachia-Infected Mosquitoes Reduces Dengue Risk by Over 70% in Urban Singapore
Posted inInfectious Diseases news Public Health

Strategic Release of Wolbachia-Infected Mosquitoes Reduces Dengue Risk by Over 70% in Urban Singapore

A large-scale cluster-randomized trial in Singapore demonstrates that releasing male Aedes aegypti mosquitoes infected with the wAlbB Wolbachia strain significantly suppresses wild-type populations and reduces the incidence of symptomatic dengue virus infection by 71-72%, offering a transformative approach to urban vector control.
Precision Immunotherapy in Pneumonia: Presepsin-Guided Anakinra Significantly Reduces Organ Dysfunction and Mortality
Posted inCritical Care Infectious Diseases news

Precision Immunotherapy in Pneumonia: Presepsin-Guided Anakinra Significantly Reduces Organ Dysfunction and Mortality

The Phase IIa INSPIRE trial demonstrates that early administration of anakinra, guided by the presepsin biomarker, reduces the risk of organ dysfunction by 30% and significantly improves 90-day survival in hospitalized pneumonia patients, marking a major step forward for precision medicine in critical care.